AU2004230254B2 - Chimeric polypeptides and their use - Google Patents

Chimeric polypeptides and their use Download PDF

Info

Publication number
AU2004230254B2
AU2004230254B2 AU2004230254A AU2004230254A AU2004230254B2 AU 2004230254 B2 AU2004230254 B2 AU 2004230254B2 AU 2004230254 A AU2004230254 A AU 2004230254A AU 2004230254 A AU2004230254 A AU 2004230254A AU 2004230254 B2 AU2004230254 B2 AU 2004230254B2
Authority
AU
Australia
Prior art keywords
cells
dna
polypeptide
cell
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004230254A
Other languages
English (en)
Other versions
AU2004230254A1 (en
Inventor
Christian Kuhne
Andras Simoncsits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADRIACELL SpA
Original Assignee
ADRIACELL SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADRIACELL SpA filed Critical ADRIACELL SpA
Publication of AU2004230254A1 publication Critical patent/AU2004230254A1/en
Application granted granted Critical
Publication of AU2004230254B2 publication Critical patent/AU2004230254B2/en
Assigned to ADRIACELL S.P.A. reassignment ADRIACELL S.P.A. Request for Assignment Assignors: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
AU2004230254A 2003-04-18 2004-04-16 Chimeric polypeptides and their use Ceased AU2004230254B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2003A000821 2003-04-18
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Publications (2)

Publication Number Publication Date
AU2004230254A1 AU2004230254A1 (en) 2004-10-28
AU2004230254B2 true AU2004230254B2 (en) 2008-10-02

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230254A Ceased AU2004230254B2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Country Status (16)

Country Link
US (3) US20060292629A1 (enExample)
EP (1) EP1616011B1 (enExample)
JP (2) JP4794432B2 (enExample)
KR (2) KR101247704B1 (enExample)
CN (1) CN100584950C (enExample)
AT (1) ATE374826T1 (enExample)
AU (1) AU2004230254B2 (enExample)
CA (1) CA2522525A1 (enExample)
CY (1) CY1107115T1 (enExample)
DE (1) DE602004009301T2 (enExample)
DK (1) DK1616011T3 (enExample)
ES (1) ES2293247T3 (enExample)
IT (1) ITMI20030821A1 (enExample)
PL (1) PL1616011T3 (enExample)
PT (1) PT1616011E (enExample)
WO (1) WO2004092194A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
WO2006087557A1 (en) * 2005-02-18 2006-08-24 Astrazeneca Ab METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
US8552168B2 (en) * 2007-05-11 2013-10-08 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
JP2017508148A (ja) 2014-02-17 2017-03-23 ユニヴェルシテ クロード ベルナール リヨン １ 組織の放射線感受性を判定するための予測的方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
MX2018012454A (es) * 2016-04-12 2019-06-10 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Constructos de fusion de mutasa de metilmalonil coenzima a (mcm) para el tratamiento de trastornos asociados con la deficiencia de mcm.
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
AU2017271678B2 (en) 2016-05-27 2021-05-06 Synthex, Inc. Protein interfaces
KR20190020727A (ko) * 2016-06-09 2019-03-04 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 b를 갖는 헤르페스 바이러스
KR20240027153A (ko) 2017-06-15 2024-02-29 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 비-바이러스 dna 삽입
AU2018355587B2 (en) 2017-10-27 2023-02-02 The Regents Of The University Of California Targeted replacement of endogenous T cell receptors
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
JP2025503456A (ja) 2021-12-16 2025-02-04 アールディーピー ファーマ アーゲー 細胞膜透過性ポリペプチド（ｃｐｐ）及びヒト治療におけるそれらの使用
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
WO2000046386A2 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
JP2006502748A (ja) * 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONAHUE S. L. ET AL. "Mitochondrial DNA ligase function in Saccharomyces cerevisiae." Nucleic Acids research, 2001, vol. 29, no. 7, pages 1582-1589 *
NISHIGORI C ET AL. "HindIII liposomes suppress delayed-type hypersensitivity responses in vivo and induce epidermal IL-10 in vitro." The Journal of Immunology, 1998, vol. 161, pages 2684-2691 *
ROSENBERG A ET AL. "T7Select phage display system: a powerful new protein display system based on bacteriophage T7." Innovations, December 1996, no. 6, pages 1-6 *
TANAKA M ET AL. "Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria." Journal of Biomedical Science, 2002, vol 9, pages 534-541 *

Also Published As

Publication number Publication date
KR20060003029A (ko) 2006-01-09
US20060292629A1 (en) 2006-12-28
KR20110074948A (ko) 2011-07-04
WO2004092194A2 (en) 2004-10-28
KR101360781B1 (ko) 2014-04-24
ATE374826T1 (de) 2007-10-15
EP1616011B1 (en) 2007-10-03
CN1768142A (zh) 2006-05-03
ES2293247T3 (es) 2008-03-16
KR101247704B1 (ko) 2013-03-26
CN100584950C (zh) 2010-01-27
EP1616011A2 (en) 2006-01-18
CA2522525A1 (en) 2004-10-28
WO2004092194A3 (en) 2005-03-17
JP4794432B2 (ja) 2011-10-19
JP2011182792A (ja) 2011-09-22
DE602004009301T2 (de) 2008-07-17
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20150018409A1 (en) 2015-01-15
AU2004230254A1 (en) 2004-10-28
DE602004009301D1 (de) 2007-11-15
JP2006523448A (ja) 2006-10-19
US20110033384A1 (en) 2011-02-10
DK1616011T3 (da) 2008-02-04
ITMI20030821A1 (it) 2004-10-19
CY1107115T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
US20110033384A1 (en) Chimeric polypeptides and their use
Huber et al. A conserved G4 DNA binding domain in RecQ family helicases
Costantini et al. Interaction of the Ku heterodimer with the DNA ligase IV/Xrcc4 complex and its regulation by DNA-PK
Liu et al. Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage
Fell et al. The Ku heterodimer: function in DNA repair and beyond
Kitagawa et al. The ATM-dependent DNA damage signaling pathway
Zheng et al. Human DNA2 is a mitochondrial nuclease/helicase for efficient processing of DNA replication and repair intermediates
US20200140835A1 (en) Engineered CRISPR-Cas9 Nucleases
US6265196B1 (en) Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
EP2526199A2 (en) Methods of generating zinc finger nucleases having altered activity
WO1996012820A1 (en) INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO
Choi et al. Meiosis-specific cohesin complexes display essential and distinct roles in mitotic embryonic stem cell chromosomes
US20120329067A1 (en) Methods of Generating Zinc Finger Nucleases Having Altered Activity
Baldwin et al. The yeast SUMO isopeptidase Smt4/Ulp2 and the polo kinase Cdc5 act in an opposing fashion to regulate sumoylation in mitosis and cohesion at centromeres
Yan et al. Analysis of the Xenopus Werner syndrome protein in DNA double-strand break repair
Sugaya et al. A temperature-sensitive mutation in the WD repeat-containing protein Smu1 is related to maintenance of chromosome integrity
US20190048048A1 (en) Fusion proteins and methods for identifying bromodomain inhibiting compounds
EP3702495A1 (en) Antibody like protein
Islam Development of Systems for Expression, Purification, and CK2-Mediated Phosphorylation of the Histone Oligomers
Kulepa Probing interactions of the BRCT protein family with damaged chromatin
Wu Roles of NBS1 and BRCA2 cancer susceptibility genes in the maintenance of genome stability
ES2363398A1 (es) Métodos y composiciones para la identificación de compuestos embriotóxicos.
Bonalli Investigations on phosphospecific interactions in the DNA damage response
Hoellerich et al. Nucleolar localization of SmMAK16 protein from Schistosoma mansoni is regulated by three distinct signals that function independent of pH or phosphorylation status
Sigvaldadóttir Functional analysis of the dREQ MITF mutant: Determination of the nuclear localization and transcription activation potential of an MITF mutant lacking three amino acids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ADRIACELL S.P.A.

Free format text: FORMER OWNER WAS: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired